A novel LMP1 antibody synergizes with mitomycin C to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factor.
A novel LMP1 antibody synergizes with mitomycin C to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factor.
复制标题
DOI：
10.3390/ijms13022208
复制
发表时间：
2012
影响因子：
5.6
通讯作者：
Feng ZQ
中科院分区：
文献类型：
--
作者：
Mao Y;Zhang DW;Wen J;Cao Q;Chen RJ;Zhu J;Feng ZQ
联合治疗成为一种有吸引力的癌症治疗策略。本研究旨在探讨丝裂霉素C（MMC）联合针对潜伏膜蛋白1（LMP 1）的新型抗体片段（Fab）对鼻咽癌（NPC）裸鼠移植瘤的抑制作用。MMC（2 mg/kg）、Fab（4 mg/kg）、MMC（2 mg/kg）+ Fab（4 mg/kg）、MMC（1 mg/kg）+ Fab（4 mg/kg）的抑制率分别为20.1%、7.3%、42.5%和40.5%。流式细胞仪分析显示，MMC和Fab联合组移植瘤细胞凋亡率为28 ± 4.12%，显著高于MMC（2 mg/kg）组（P < 0.01）。免疫组化染色显示，与Fab（4 mg/kg）组相比，联合治疗组鼻咽癌移植瘤VEGF表达明显受到抑制（P < 0.05）。结论：MMC和Fab均能抑制鼻咽癌移植瘤的生长，二者联合治疗具有明显的协同抗肿瘤作用，其机制可能与诱导肿瘤细胞凋亡和下调VEGF表达有关。这些结果表明，利用传统的化疗药物和抗体靶向治疗的新的联合治疗可能是一个有前途的策略，治疗鼻咽癌。
Combined therapy emerges as an attractive strategy for cancer treatment. The aim of this study was to investigate the inhibitory effects of mitomycin C (MMC) combined with a novel antibody fragment (Fab) targeting latent membrane protein 1 (LMP1) on nasopharyngeal carcinoma (NPC) xenograft nude mice. The inhibitory rates of MMC (2 mg/kg), Fab (4 mg/kg), MMC (2 mg/kg) + Fab (4 mg/kg), and MMC (1 mg/kg) + Fab (4 mg/kg) were 20.1%, 7.3%, 42.5% and 40.5%, respectively. Flow cytometry analysis showed that the apoptotic rate of xenograft tumor cells in the MMC and Fab combination group was 28 ± 4.12%, significantly higher than the MMC (2 mg/kg) group (P < 0.01). Immunohistochemical staining showed that VEGF expression in NPC xenografts was significantly inhibited in the combination group compared to the Fab (4 mg/kg) group (P < 0.05). In conclusion, both MMC and Fab could inhibit NPC xenograft tumor growth in vivo and combination therapy showed apparent synergistic anti-tumor effects, which may be due to the induction of tumor cell apoptosis and the downregulation of VEGF expression. These results suggest that the novel combined therapy utilizing traditional chemotherapeutics and antibody-targeted therapy could be a promising strategy for the treatment of NPC.
登录
查看更多内容
影响因子：
8
作者：
Niu, GL;Wright, KL;Yu, H
通讯作者：
Yu, H
影响因子：
3.8
作者：
Pallis, Athanasios G.;Agelaki, Sophia;Georgoulias, Vassilis
通讯作者：
Georgoulias, Vassilis
影响因子：
50.5
作者：
Ma, B. B. Y.;Kam, M. K. M.;Chan, A. T. C.
通讯作者：
Chan, A. T. C.
影响因子：
3.2
作者：
Friedrich, M;Villena-Heinsen, C;Reichrath, J
通讯作者：
Reichrath, J
影响因子：
5.6
作者：
Pircher A;Hilbe W;Heidegger I;Drevs J;Tichelli A;Medinger M
通讯作者：
Medinger M